Balaxi Pharma
Balaxi Pharma Q3 FY26: Revenue ₹72.54 Cr, PAT ₹5.36 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaxi Pharma's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Q3 FY25 Financials (Page 20): - Revenue: ₹73.29 crore - EBITDA: ₹7.93 crore (10.8% margin) - Profit After Tax (PAT): ₹5.36 crore (7.3% margin) - Q3 FY26 Financials (Page 19): - Revenue: ₹72.54 crore (1% YoY decline vs.
From Balaxi Pharma's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19).
- Q3 FY26 QoQ growth: 29% increase from ₹56.18 crore in Q2 FY26 (Page 19).
- Q3 FY25 revenue: ₹73.29 crore (Page 20).
- No explicit volume figures stated.
- Outlook: Management confident of margin recovery and sustainable long-term growth driven by improving regional traction, operating leverage benefits, commissioning of the new formulation facility (Page 19).
2 more points from Balaxi Pharma's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Balaxi Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Established the Company’s first pharmaceutical formulation manufacturing facility in Hyderabad, located in a Pharma SEZ near Jadcherla.
- Facility focuses on General Oral Solid Dosage (OSD) formulations targeting Latin American and African markets.
- Plant qualification and validation are complete; final audit readiness achieved in Q3 FY26 including manufacturing, QA, QC, microbiology documentation, and equipment/system qualification.
- Stability data for initial test batches generated and satisfactory.
- Capex amount mentioned: INR 47.57 crore raised through Preferential issue for expansion and manufacturing facility.
- Transition from “Asset Light” to “Asset Right” strategy to drive backward integration of supply chain.
2 more points from Balaxi Pharma's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Balaxi Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaxi Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹73 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaxi Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Ind-Swift Laboratories Ltd (Q3 FY26)
Q2 FY26 Revenue: ₹152.64 Cr (Total Income: ₹170.50 Cr), with a year-on-year (Y-o-Y) increase of 1.91%. Key investor presentation takeaways from Ind-Swift Labora
Arthneeti Pro · Annual
Balaxi Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaxi Pharma Q3 FY26 results?
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Q3 FY25 Financials (Page 20): - Revenue: ₹73.29 crore - EBITDA: ₹7.93 crore (10.8% margin) - Profit After Tax (PAT): ₹5.36 crore (7.3% margin) - Q3 FY26 Financials (Page 19): - Revenue: ₹72.54 crore (1% YoY decline vs.
What is Balaxi Pharma share price analysis?
Balaxi Pharma currently shows a neutral. The stock trades at a P/E of 50.2 with a market cap of ₹122 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaxi Pharma planning capital expenditure?
Established the Company’s first pharmaceutical formulation manufacturing facility in Hyderabad, located in a Pharma SEZ near Jadcherla.
Keep Balaxi Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.